Literature DB >> 23072976

Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat.

Ludivine S Breger1, Stephen B Dunnett, Emma L Lane.   

Abstract

Abnormal involuntary movement (AIM) rating scales are frequently used to study the mechanisms underlying L-DOPA-induced dyskinesia (LID) in 6-OHDA lesioned rodents and the propensity of novel treatments for Parkinson's disease to induce or alleviate similar abnormal behaviours. Despite the existence of at least one well validated method, other AIM scales are also in use. Moreover, there have been developments and variations in the original scales and their methods of use, without re-validation. In this study, 6-OHDA medial forebrain bundle lesioned Sprague-Dawley rats were treated with chronic L-DOPA 6 mg/kg/day for 5 weeks followed by 12 mg/kg/day for another 5 weeks. Rats were assessed weekly by simultaneous ratings on four published AIM and stereotypy scales with concurrent recording of rotation, over 3 hours following L-DOPA injection. Three contemporary AIM scales have then been validated pharmacologically using agents that are known to reduce LID clinically and in primates (amantadine) or to interfere with the activity of L-DOPA (the D(1) and D(2) dopamine receptor antagonists, SCH-23390 and raclopride) respectively. We also demonstrate that AIM, stereotypic and rotational behaviour are distinct motor dysfunctions induced by chronic and acute treatment of L-DOPA, and should be assessed separately. The undertaking of assessments at multiple time points is essential especially when testing the efficacy of new potential anti-dyskinetic treatments. Importantly critical to all AIM and rotation testing is the internal validation of both the scale being used and the environment being used.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23072976     DOI: 10.1016/j.nbd.2012.10.013

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  14 in total

1.  D-512, a novel dopamine D2/3 receptor agonist, demonstrates greater anti-Parkinsonian efficacy than ropinirole in Parkinsonian rats.

Authors:  David Lindenbach; Banibrata Das; Melissa M Conti; Samantha M Meadows; Aloke K Dutta; Christopher Bishop
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

2.  Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.

Authors:  Hanna Iderberg; Natallia Maslava; Analisa D Thompson; Michael Bubser; Colleen M Niswender; Corey R Hopkins; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones; M Angela Cenci
Journal:  Neuropharmacology       Date:  2015-03-04       Impact factor: 5.250

3.  D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson's disease.

Authors:  Irene Sebastianutto; Elise Goyet; Laura Andreoli; Joan Font-Ingles; David Moreno-Delgado; Nathalie Bouquier; Céline Jahannault-Talignani; Enora Moutin; Luisa Di Menna; Natallia Maslava; Jean-Philippe Pin; Laurent Fagni; Ferdinando Nicoletti; Fabrice Ango; M Angela Cenci; Julie Perroy
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

4.  Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.

Authors:  Kristin B Dupre; Corinne Y Ostock; Jessica A George; Karen L Eskow Jaunarajs; Cara M Hueston; Christopher Bishop
Journal:  ACS Chem Neurosci       Date:  2013-04-01       Impact factor: 4.418

5.  Systems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia.

Authors:  Martin Tamtè; Ivani Brys; Ulrike Richter; Nedjeljka Ivica; Pär Halje; Per Petersson
Journal:  J Neurophysiol       Date:  2016-01-06       Impact factor: 2.714

6.  Axial levodopa-induced dyskinesias and neuronal activity in the dorsal striatum.

Authors:  Stephanie L Alberico; Young-Cho Kim; Tomas Lence; Nandakumar S Narayanan
Journal:  Neuroscience       Date:  2016-12-09       Impact factor: 3.590

7.  Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.

Authors:  Kristin B Dupre; Ana V Cruz; Alex J McCoy; Claire Delaville; Colin M Gerber; Katherine W Eyring; Judith R Walters
Journal:  Neurobiol Dis       Date:  2015-11-14       Impact factor: 5.996

Review 8.  Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease.

Authors:  Xiomara A Perez
Journal:  Neuropsychol Rev       Date:  2015-11-09       Impact factor: 7.444

9.  Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease.

Authors:  Emma L Lane; David J Harrison; Elena Ramos-Varas; Rachel Hills; Sophie Turner; Mariah J Lelos
Journal:  Mov Disord       Date:  2021-11-12       Impact factor: 9.698

Review 10.  Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.

Authors:  Clare J Finlay; Susan Duty; Anthony C Vernon
Journal:  Front Neurol       Date:  2014-06-12       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.